Novartis’ Tislelizumab Faces FDA Hurdle in First-Line NSCLC Monotherapy
Novartis disclosed during its Q2 2022 earnings call that the U.S. FDA deemed clinical data...
Latin America Accelerates COVID-19 Fight with Vaccine and Treatment Initiatives Across the Region
Latin America is ramping up its contributions to the worldwide race for COVID-19 vaccines and...
Exegenesis Bio Secures Multi-Million Dollar Series B Financing for Gene Therapy Pipeline
Exegenesis Bio Inc., a leading gene therapy company, has successfully completed a Series B financing...
Genscript’s CAR-T Therapy JNJ-4528 Demonstrates 100% Effective Rate in Long-Term Myeloma Study
Genscript Biotech Corporation (HKG: 1548), a leading China-based Contract Development and Manufacturing Organization (CDMO), has...
Asymchem Laboratories Secures RMB 2.31 Billion Private Placement with Hill House Capital Subscription
Asymchem Laboratories (Tianjin) Co., Ltd, a renowned Contract Development and Manufacturing Organization (CDMO) based in...
Innovent Biologics and Eli Lilly & Co.’s Tyvyt Achieves Primary Endpoints in Phase II ESCC Clinical Study
Innovent Biologics (HKG: 1801), a prominent biotech firm headquartered in Suzhou, China, and Eli Lilly...
Luye Pharma Expands Latin American Reach with Exclusive Seroquel Promotion Agreement in Brazil and Mexico
Luye Pharma Group (HKG: 2186), a leading Chinese pharmaceutical conglomerate, has declared that its wholly-owned...
Zai Lab’s Optune Approved by China’s NMPA, Offering New Hope for Glioblastoma Patients
Zai Lab Ltd (NASDAQ: ZLAB), a biopharmaceutical company based in China, has received approval from...
Enhancing Clinical Trial Success: CDE’s New Adaptive Design Framework Opens for Comment
The newly proposed guidelines are designed to be applicable across a spectrum of confirmatory clinical...
Thermo Fisher Scientific Develops Serology Test to Detect COVID-19 Antibodies in Collaboration with WuXi Diagnostics and Mayo Clinic
Thermo Fisher Scientific Inc., a titan in the US device industry and listed on the...
Cuban-Chinese Pharma Synergy: Joint R&D and Sales Initiative Targets USD 24.53 Billion in Sales
In a significant move to bolster its innovation pipeline, Guangzhou Pharmaceutical Holdings Ltd. has entered...
Guangzhou Pharma and BioCubaFarma Chart New Course with Joint Biologics R&D and Exchange Deal
Guangzhou Pharmaceutical Holdings Ltd., a prominent player in China’s pharmaceutical sector, has inked a strategic...
Hanx Biopharmaceuticals’ HX009 Receives NMPA Clinical Trial Approval for PD-1/CD47 Bispecific Antibody
China-based Hanx Biopharmaceuticals Co., Ltd has announced that its self-developed anti PD-1/CD47 bispecific antibody drug,...
LanssonPharm Secures Series A Funding to Accelerate CNS Drug Development
LanssonPharm, a company dedicated to the development of central nervous system (CNS) drugs, has announced...
China’s Ministry of Health Tightens Organ Transplant Regulations with Expert Conference
Shi Bingyi, a distinguished Member of the National Committee of the CPPCC (Chinese People’s Political...
China Launches Unprecedented Multi-Center Hypertension Study with Global Implications
On April 2nd, a landmark healthcare initiative, the “Hypertension Prevention and Treatment Research” project, commenced...
China Biopharma Posts 216% Revenue Increase, Eyes US$10 Million in 2007 with Vaccine Distribution and New Treatments
China Biopharma Corporation, trading on the OTC Bulletin Board under the symbol (CBPC.OB), announced a...
Shanghai to Launch China’s Largest ADR Database, Enhancing Pharmaceutical Oversight
Shanghai is advancing towards a significant milestone in pharmaceutical safety with plans to establish the...
China Unveils TCM Development Guidelines: A Strategic Defense of Traditional Medicine
In a strategic move to assert the value and historical significance of Traditional Chinese Medicine...
India Launches Anti-Dumping Campaign Against Chinese Vitamin B12 and Ceftriaxone Sodium Producers
In a strategic response to India’s Ministry of Commerce and Industry’s (MOFCOM) anti-dumping ruling against...